NuScale Power Is Interesting, but Here's What I'd Buy Instead

NuScale Power, developer of small modular nuclear reactors, secured U.S. NRC approval last year for a 462‑megawatt SMR design but remains years from commercialization and trades at a roughly $5.6 billion market capitalization after a ~65% decline from its peak. Axcelis Technologies (ACLS), an ion‑implantation equipment supplier, reported a 17% year‑over‑year revenue decline in Q3 and expects Q4 revenue to fall again, but is pivoting from EV‑driven demand toward AI semiconductor opportunities, carries a ~20x P/E amid investor pessimism, and is pursuing a merger with Veeco to broaden its semiconductor equipment exposure.

Analysis

Market structure: The immediate winners are semiconductor-equipment suppliers that service AI/datacenter fabs (ACLS, VECO post-close, AMAT/KLA indirectly) while speculative utility/nuclear plays (SMR) face long lead times and capital-intense project risk. If ACLS converts AI bookings at even a 5-10% incremental share of global ion-implant demand over 12–24 months it can materially lift margins vs current 20x P/E; conversely SMR needs multi-year of offtake and project financing before revenue, compressing its pricing power today. Supply/demand: chip-capex is lumpy—order backlogs and tool lead times (6–18 months) amplify cyclical moves; a renewed AI capex wave would tighten supply for ion implanters and support ACLS pricing for 2–3 quarters. Cross-assets: stronger AI capex lifts industrial equities and EM exporters of semiconductor components, tightens corporate credit spreads for equipment makers, and raises implied vols on semicap options; SMR delays keep long-dated project bonds and uranium demand muted near-term.

Risk assessment: Tail risks include NRC/regulatory reversals or major construction overruns for SMR (valuation shock >50%) and ACLS merger-integration failure or an AI capex soft patch that sustains revenue declines >15% YoY. Time horizons diverge: expect market-moving Qs for ACLS within 1–6 months (earnings, order flow), while SMR outcomes play out over 2–7 years (project awards, EPC contracts). Hidden dependencies: ACLS growth depends on foundry design wins and supply-chain wafer-node transitions; VECO merger could dilute focus and increase execution risk in the next 12 months. Catalysts: large fab order announcements, AI hyperscaler capex guidance, NRC plant licensing milestones, or VECO/ACLS combined backlog disclosures can flip consensus quickly.

trade implications: Direct long: establish a tactical 2–3% long position in ACLS (NASDAQ: ACLS) sized to portfolio risk, layering buys on 10–15% pullbacks and targeting a 30–40% upside if AI bookings accelerate within 12–24 months. Direct short / avoid: avoid initiating long SMR (NYSE: SMR); consider a small asymmetric short via 9–12 month puts (strike ~20–30% below spot) sized to 0.5–1% portfolio to hedge nuclear commercialization disappointment. Pair trade: long ACLS vs short AMAT (or broad semicap ETF like SOXX) if you expect ACLS to gain share—use 6–12 month call spreads on ACLS (buy LEAP calls, sell nearer-term calls) financed by selling short-dated calls on AMAT to reduce cost. Options: buy ACLS 12-month 25–35% OTM call spreads to limit premium; sell ACLS near-term covered calls only after price appreciation to harvest theta.

Contrarian angles: The market underestimates ACLS’ ability to reallocate capacity from EV to AI fabs—if AI orders materialize, the consensus 20x P/E could expand to 25–30x within 12–18 months, implying 30–60% upside; the market overprices SMR’s near-term revenue potential given persistent financing and supply-chain hurdles. Historical parallel: semicap recoveries post-2016 show rapid earnings re-rating within 9–18 months once hyperscaler capex resumes, which supports a tactical overweight in quality semicap names with visible bookings. Unintended consequences: an ACLS+VECO integration misstep or hyperscaler inventory destocking could flip this trade; size positions to withstand a 30% drawdown and use option structures to cap downside.

Key Decisions for Investors

• Establish a tactical 2–3% long position in Axcelis Technologies (ACLS) now, dollar-cost average on any 10–15% pullbacks, with a 12–24 month target of +30–40% if AI fab orders convert; trim to lock profits at +40%.
• Avoid initiating new long positions in NuScale Power (SMR); instead buy 9–12 month put options with strikes ~20–30% below current spot sized to 0.5–1% of portfolio as an asymmetric hedge against regulatory or commercialization failure.
• Execute a pair trade: go long ACLS (via 12-month call spread, buy 2027 LEAP call and sell nearer-term call to finance) and short-equivalent exposure to AMAT or SOXX (sell short-dated calls or take a small short position) to capture potential ACLS share gains in ion implantation over 6–18 months.
• Monitor three near-term catalysts over the next 90 days before increasing size: ACLS quarterly bookings/order disclosure, any VECO merger integration updates, and hyperscaler capex commentary; if ACLS reports sequential order-book growth >10% QoQ, increase position to 4–5%.
• Reduce speculative clean-energy/nuclear allocations by 50% in tactical portfolios and reallocate that capital to semicap/AI infrastructure names if ACLS or peers show sustained order momentum within two quarters.